1stOncology™: Cancer Intelligence Service – Page 9862 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

On March 16, 2021 Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, reported the closing of its previously announced underwritten public offering of 2,078,214 shares of its common stock, offered at a price of $7.00 to the public, which includes the full exercise of the underwriter’s over-allotment option to purchase additional shares (Press release, Cyclacel, MAR 16, 2021, View Source [SID1234576813]). The gross proceeds to the Company from this offering are approximately $14.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. Existing and new institutional investors participated in the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Cyclacel intends to use the net proceeds from this offering to support the Company’s growth strategy and for working capital and general corporate purposes, including research and development expenses, and capital expenditures.

Oppenheimer & Co. Inc. acted as the sole book-running manager, and Ladenburg Thalmann & Co. Inc., Roth Capital Partners, and Brookline Capital Markets, a division of Arcadia Securities, LLC acted as co-managers for the public offering.

This offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-231923) previously filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective by the SEC on June 21, 2019. A preliminary prospectus supplement relating to the offering was filed with the SEC on March 11, 2021 and is available on the SEC’s website at www.sec.gov. The final prospectus supplement relating to the offering was filed with the SEC and is available on the SEC’s web site at www.sec.gov. Before investing in the offering, you should read the prospectus supplement and the accompanying prospectus in their entirety as well as the other documents that the Company has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering. Copies of the final prospectus supplement and accompanying prospectus may also be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY, 10004, by telephone at (212) 667-8055, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021

On March 16, 2021 CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, reported that the company will release its fourth quarter 2020 financial results after the market closes on Tuesday, March 30, 2021 (Press release, CohBar, MAR 16, 2021, View Source [SID1234576812]). Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.

Details for the Conference Call and Slide Presentation:

Go to www.webex.com, click on the ‘Join a Meeting’ button and enter meeting number 145 355 3814 and password CWBR, or
Go to www.cohbar.com and click on Q4 2020 Shareholder Presentation at the top of homepage.
For individuals participating in the Investor Call and Slide Presentation, please call into the conference audio and log into Webex approximately 10 minutes prior to its start.

An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on March 30, 2021, through 11:59 p.m. Eastern Time on April 20, 2021. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13717040. The audio recording along with the slide presentation will also be available at www.cohbar.com during the same period.

Dr. Henry Ji to Participate in the CEO Roundtable during WuXi Healthcare Forum 2021 on March 17, 2021

On March 16, 2021 Sorrento Therapeutics, Inc. (Nasdaq: SRNE), reported that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference (Press release, Sorrento Therapeutics, MAR 16, 2021, View Source [SID1234576802]):

CEO Roundtable during WuXi Healthcare Forum 2021

Dr. Henry Ji will participate in the CEO forum this evening and provide an update on Sorrento’s programs. Sorrento’s Management will be available during the CEO roundtable to answer questions.

Interested investors and industry partners can register through the following link:

View Source

Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer

On March 16, 2021 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, reported a second clinical trial collaboration and supply agreement with subsidiaries of Merck & Co., Inc., Kenilworth, NJ, USA (known as "MSD" outside the United States and Canada) (Press release, Immutep, MAR 16, 2021, View Source [SID1234576773]). Under the agreement, Immutep will conduct a new Phase IIb clinical trial in 1st line HNSCC patients, as initially described in the ASX announcement dated 28 September 2020.

The trial, called TACTI-003 (Two Active Immunotherapies), will be a 1:1 randomised, controlled clinical study in approximately 160 1st line HNSCC patients. It will evaluate the safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321), when given in combination with MSD’s KEYTRUDA (pembrolizumab), compared to pembrolizumab alone. TACTI-003 will take place in 20+ clinical sites in the United States, Australia and Europe, and the first patient is expected to be enrolled in mid-2021.

The combination of efti and KEYTRUDA is also being evaluated in Immutep’s ongoing Phase II TACTI-002 study. The promising clinical results generated to date from the TACTI-002 trial have prompted the initiation of the new TACTI-003 trial. The combination brings together two immuno-oncology treatments with complementary mechanisms of action at two different positions in the cancer immunity cycle. Efti is a first-in-class antigen presenting cell activator which stimulates cancer-fighting T cells, while KEYTRUDA is an anti-PD-1 therapy which blocks the immunosuppressive PD-1 pathway.

"We are excited to be deepening our collaboration with MSD through this second agreement and the TACTI-003 clinical trial. Advancing to this later stage Phase IIb trial will allow us to explore the combination therapy in the commercially relevant 1st line therapy setting which has a high unmet medical need," said Immutep CEO Marc Voigt.

HNSCC is the sixth most common cancer by incidence worldwide, with 890,000 new cases and 450,000 deaths reported in 2018.1,2,3 HNSCC is an aggressive, genetically complex, and difficult to treat cancer.4 Furthermore, HNSCC is associated with high levels of psychological distress and compromised quality of life (QOL).5 As such, patients with HNSCC are very much in need of improved treatment options.

Nucleai Partners With Sheba Medical Center’s ARC Innovation Center For a New Strategic Data Collaboration

On March 16, 2021 Israeli artificial intelligence firm Nucleai reported that it is partnering with Sheba Medical Center’s ARC Innovation Center for a new strategic data collaboration (Press release, Debiopharm, MAR 16, 2021, https://www.jpost.com/health-science/israeli-ai-firm-nucleai-sheba-launch-partnership-for-data-collaboration-661267 [SID1234576769]).

This new partnership will see Nucleai – which works in powered image analysis – gain access to millions of patient records at Israel’s largest hospital, which will include pathology images, clinical data, genomics and radiomics, along with other data modalities.

This is not the first time Nucleai and Sheba have collaborated. The two have an existing collaboration to work on identifying the histological biomarkers that can predict the body’s response to immunotherapy for non-small-cell lung cancer patients.

This was done with the help of Sheba’s Institute of Pathology, a world leader in the field that acts as a center for diagnosis and research for pathology precision medicine.
Together, Nucleai and the ARC Innovation Center formed a team led by the Pathology Institute head Prof. Iris Barshack along with many of Sheba’s and Nucleai’s specialists to identify biomarkers in other cancer types and treatment modalities.

One success to come out of this partnership was a successful study that demonstrated the prediction efficiency of tumor microenvironment AI-based analysis for breast cancer. These findings were presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 conference.

Together, Sheba and Nucleai are working to advance the study of technological and AI-based solutions to aid in the discovery of histological biomarkers.